Skip to main content
Premium Trial:

Request an Annual Quote

Korea's Panagene Adds miRNA Array Lines for Cancer, Stem-Cell Research


This story was originally published on August 7.

By Justin Petrone

SOUTH SAN FRANCISCO, Calif. — Panagene, a nine-year-old life-sciences firm specializing in peptide nucleic-acid products, this month launched a kit for profiling microRNAs in stem cells, according to a company official.

Dalsoo Kim, marketing director for the Daejeon, Korea-based firm, said the company now sells a PANArray miRNA expression-profiling kit for surveying stem cell-related miRNAs. The launch follows the debut of a kit for profiling cancer-related miRNAs in June.

Kim spoke to BioArray News during Select Biosciences' Microarray World Congress, held here last week. Panagene exhibited at the conference.

Though the company sells a few other array kits, such as a PANArray HPV genotyping kit for identifying different strains of human papillomavirus, as well as custom PANArrays, Panagene has to date mostly focused on selling services related to its experience in peptide nucleic acids, Kim said.

"MiRNA is the hottest area in molecular biology right now," Kim said, explaining the firm's rationale for entering a market that is dominated by firms such as Exiqon, Agilent Technologies, Febit, Affymetrix, Illumina, and Life Technologies' Invitrogen division.

According to Kim, what sets Panagene's arrays apart from competitors’ is their use of PNA. PNA is a nucleic acid analogue that mimics DNA. The negatively charged sugar phosphate backbone of a DNA molecule is replaced with a neutral one consisting of repeated N-(2-aminoethyl) glycal units linked by peptide bonds, features that make the molecule "more chemically and biologically stable than DNA," he said.

While Panagene's service business is still its main focus, Kim said that Panagene will add more array kits in the future to serve clients who prefer to run the chips in house. "We will keep adding PNA-based kits as there is a good opportunity for practical industrial use," he said.

The next PANArray in the pipeline will offer cytochrome P450 genotyping for drug metabolism studies, he said. He did not discuss a launch date for the new product.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.